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Abstract
Background: Emotional disorders (ED) are among the most prevalent mental disorders. However, less than 50% of people
suffering from ED receive the appropriate treatment. This situation has led to the development of new intervention proposals
based on the transdiagnostic perspective, which tries to address the underlying processes common to ED. Most of these
programs focus primarily on down-regulating negative affectivity, rather than increasing strengths and up-regulating positive
affectivity. The data suggest the existence of disturbances in positive affectivity in these disorders, and so new interventions
focusing on these problems are greatly needed. It is also essential to provide assistance to all the people in need. Information
and Communication Technologies can be very useful. This study aims to evaluate the efficacy of a transdiagnostic Internet-
based treatment for ED in a community sample. The protocol includes traditional CBT components, as well as a specific
component to address positive affect. We intend to test this protocol, including this specific component or not, versus a waiting
list control group. Moreover, we aim to test the differential effect of this specific component, and study the effectiveness (in
terms of patients’ acceptance) of using a self-applied Internet-based program. This paper presents the study protocol.
Methods: The study is a randomized controlled trial. 207 participants will be randomly assigned to: a)
Transdiagnostic Internet-based protocol (TIBP), b)Transdiagnostic Internet-based protocol + positive affect component
(TIBP + PA), or c)a Waiting List control group (WL). Primary outcomes measures will be the BDI-II, the BAI, and the
PANAS. Secondary outcomes will include diagnosis-specific measures of the principal disorder. Participants’ treatment
acceptance will also be measured. Participants will be assessed at pre-, post-treatment, and 3- and 12- month follow-
ups. The data will be analyzed based on the Intention-to-treat principle. Per protocol analyses will also be performed.
Discussion: To the best of our knowledge, this is the first study of a transdiagnostic Internet-based treatment for ED
with a specific component to up-regulate positive affectivity. This intervention could contribute to improve the
efficiency and effectiveness of current treatment programs for ED, promote the dissemination of EBTs, and help to
decrease the high prevalence of ED.
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Lifetime prevalence estimates for emotional disorders
(ED), defined as anxiety and unipolar mood disorders,
are quite high (anxiety disorders, 28.8%; mood disorders,
20.8%), with comorbidity rates ranging between 40 and
80% [1]. These disorders disrupt the lives of millions of
people each year, and they are one of the main causes of
disability worldwide [2, 3].
In the past few decades, evidence-based psychological
treatments (EBTs) have been shown to be effective in
the treatment of ED [4]. This development can be con-
sidered a significant advance in addressing the large
worldwide treatment needs [5]. However, the scale of
these treatments is not sufficient to reduce the disease
burden of mental disorders [6]. Less than 50% of people
suffering from ED receive adequate treatment [7], and
this percentage is much lower in adolescents, older
adults, people with a lower socio-economic status, and
people from ethnic minorities [8].
These low levels of successful dissemination of EBTs
can be explained by their costs, the duration of the treat-
ments, and the lack of well-qualified professionals [9].
This is especially problematic in everyday clinical prac-
tice and can explain why EBTs are under-utilized [10]. It
is not surprising, therefore, that this continued lack of
widespread availability of EBTs has raised the need to
implement innovative and even radical solutions to en-
sure that the aid reaches all those in need [8, 11, 12].
There is a compelling need for approaches that go be-
yond “one-to-one” psychotherapy (either with a patient,
a family, or a group) and develop a new portfolio to ad-
minister EBTs [6].
Different EBTs targeting specific anxiety and mood
disorders have been developed [13–16]. Each diagnosis-
specific treatment manual requires the use of separate
handbooks, workbook, and protocols, and therapists
must be trained in the use of each of them, which may
hinder widespread dissemination of EBTs [9].
In recent years, new proposals have emerged for trans-
diagnostic treatments that emphasize the essential pro-
cesses underlying different disorders. In the field of ED,
studies emphasize that these disorders share important
characteristics, and that this overlap emerges from
common biological and psychological vulnerabilities
[14, 17, 18]. Barlow summarizes the commonalities in
the etiology of ED in the model referred to as “triple
vulnerabilities”. This theory encompasses a generalized
biological vulnerability (involving nonspecific genetic con-
tributions to the development of anxiety and negative
affect), a generalized psychological vulnerability (associ-
ated with early life experiences under certain conditions),
and a specific psychological vulnerability emerging from
early learning [14]. There is evidence that the two
generalized vulnerabilities are involved in the development
and expression of the ED [18, 19].
People with ED have higher levels of neuroticism/
negative affect/behavioral inhibition (N/NA/BI) [18], and
they experience negative emotions more intensely and
frequently [20, 21], accept emotional experiences to a
lesser extent [22], associate the experience of living with
more negative emotions [23], use cognitive and behav-
ioral strategies to reduce the impact of negative emo-
tions [24], and show intolerance to uncertainty, leading
to an increase in negative affect [25]. In short, people
with ED tend to react negatively to their emotions and
are more likely to use maladaptive emotion regulation
strategies. These strategies, in turn, increase the fre-
quency/intensity of negative emotions. Some authors
have argued that this functional relationship may be
driven by neuroticism, which would be the core of the
ED [26].
By contrast, the role of extraversion/positive affect/be-
havioral activation (E/PA/BA) in ED has also been
pointed out. A meta-analysis indicated that most indi-
viduals with an ED show low levels of E/BA [27]. The
data suggest that alterations in PA are observed in many
disorders [28]. Low levels of PA predict the onset of de-
pression [29], dampen positive emotions, are maladap-
tive, and increase the severity of the problem [30],
whereas high PA is associated with better health, both
physical and psychological, and greater well-being [31].
Despite the importance of disturbances in positive
affectivity in ED, few studies focus on promoting PA.
Based on the transdiagnostic perspective, Barlow’s
team designed the Unified Protocol (UP): a transdiag-
nostic, emotion-focused, cognitive-behavioral treatment
for ED that emphasizes the role of emotion regulation
[9, 26, 32]. The UP focuses on four essential aspects that
have the general purpose of down-regulating NA: ad-
dressing emotional avoidance, promoting cognitive flexi-
bility, and facilitating exposure to avoided situations and
sensations. Moreover, it places special emphasis on in-
creasing present-focused emotional awareness. The UP
has been tested, and results indicate that it is effective
[33], with improvements maintained at 18-month
follow-up [34]. Moreover, the effect of the UP has been
shown on the two temperament dimensions of N/BI and
E/BA [35].
The data suggest that a transdiagnostic treatment for
ED might be more widely effective across diverse mental
health problems, in other words, treatments aimed at
addressing different disorders with a single protocol
[36]. Some meta-analyses have been conducted on the
efficacy of transdiagnostic protocols for anxiety disorders
[37] and for anxiety and/or depression [38–40].
Nevertheless, these transdiagnostic protocols have fo-
cused on reducing NA, but less attention has been paid
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to promoting PA or modifying risk factors. As the World
Health Organization’s definition of mental health
expresses, mental health is more than just the absence of
mental illness [41]. It is not surprising, therefore, that
well-being and positive functioning are considered core
elements of mental health. As Southwick and Charney
[42] point out, the use of procedures to promote resili-
ence (such as positive emotions and optimism) can be
useful in the treating ED and in generating protective
factors. The benefits may be associated with a reduction
in the risk of developing mental symptoms and disorders
[43, 44]. However, as stated above, interventions that in-
clude components to up-regulate PA have been missing
or very scarce in the clinical setting.
Taking all this into consideration, it is necessary to de-
velop and test treatment components focused on enhan-
cing protective factors and resilience and mitigating risk
factors. Literature has highlighted the potential import-
ance of positive emotionality as a treatment component
[45, 46].
To date, the dominant delivery format in psychother-
apy has been individual face-to-face contact; however, it
is much more expensive and time-consuming than other
formats, such as guided self-help and Internet-based
treatments [47]. Recently, research has shown that Infor-
mation and Communication Technologies (ICT) can fa-
cilitate the availability of EBTs [6, 48, 49]. Specifically,
some literature suggests that the Internet can be used
for the assessment and treatment of clinical conditions
[50]. Internet-based treatments are interventions con-
ducted over the Internet with more or less therapist in-
volvement and support [51]. The evidence strongly
suggests that Internet-based treatments are effective in
the treatment of depression and anxiety disorders [52].
Moreover, data from meta-analyses reveal that these in-
terventions are as efficacious as face-to-face traditional
treatments [53–55].
We have developed an online psychological treatment
protocol for individuals with a diagnosis of ED [56],
major depression disorder (MDD), dysthymic disorder
(DD), obsessive-compulsive disorder (OCD), and four
anxiety disorders: panic disorder (PD), agoraphobia
(AG), generalized anxiety disorder (GAD), social anxiety
disorder (SAD), anxiety disorder not otherwise specified
(ADNOS), and (unipolar) mood disorder not otherwise
specified (MDNOS).
This treatment protocol includes two types of compo-
nents: one based on classical perspectives for down-
regulating NA and the other aimed at up-regulating PA.
The protocol can be applied either in its traditional for-
mat (Transdiagnostic Internet-based Protocol –TIBP–) or
by including both of these components (Transdiagnostic
Internet-based Protocol + Positive Affect Component –
TIBP + PA–). Moreover, we have developed an
adaptation of the treatment protocol that can be applied
online over the Internet. We can thus reach community
samples, that is, people who suffer from an ED but are
not receiving primary or specialized care.
We intend to study the effect of both treatments in terms
of efficacy for depressive and anxious symptomatology.
Moreover, we aim to assess the effects of the specific treat-
ment component designed for up-regulating PA. Finally,
the effectiveness of the Internet-based program developed
to apply the treatment protocol over the Internet with min-
imal support by the clinician will be studied. We
hypothesize that: a) both self-applied protocol modalities
(TIBP and TIBP + PA) will be more effective than the wait-
ing list control condition in the treatment of ED; b) both in-
terventions will result in significant improvements in
depressive and anxious symptomatology at post- treatment,
and these results will be maintained at 3- and 12- month
follow-ups; c) the TIBP + PA will significantly outperform
the TIBP group on PA measures; and d) both protocols will
be well accepted, with no statistical differences between
conditions. In this article, we present the study protocol.
Methods/Design
Study design
A three-armed randomized controlled trial (RCT) will be
conducted. Participants will be randomly allocated to one
of three conditions: a) Transdiagnostic Internet-based proto-
col (TIBP), b)Transdiagnostic Internet-based Protocol + Posi-
tive Affect component (TIBP + PA), and c) Waiting List
control condition (WL). For ethical reasons, participants in
the control condition will be offered the possibility of re-
ceiving the treatment protocol. Block randomization will be
performed within each stratum in order to ensure that all
primary diagnoses are equally represented across condi-
tions. Measures will be taken at post-randomization, after
the treatment, and at 3- and 12-month follow-ups, in order
to test whether the improvements achieved during the ther-
apy are maintained in the long term.The study flowchart is
shown in Fig. 1. The study will be conducted following the
CONSORT statement (Consolidated Standards of Report-
ing Trials, http://www.consort-statement.org) [57, 58] the
CONSORT-EHEALTH guidelines [59], and the SPIRIT
guidelines (Standard Protocol Items: Recommendations for
Interventional Trials) [60, 61].
Sample size
To determine the sample size, the effect sizes found
in the literature have been considered. An RCT using
the UP in a traditional face-to-face approach [33] ob-
tained effect sizes of 0.56 for anxiety, measured with
the BAI, and 1.11 for depression, measured with BDI-
II. The mean effect size indicated in a recent meta-
analysis [39] comparing transdiagnostic computerized
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cognitive-behavior therapy (CBT) to waitlist control
was g = .93 for anxiety and g = .88 for depression.
Adopting a more conservative approach than those
of the aforementioned studies, we assumed an effect
size of 0.5 (Hedges’ g), which, following Cohen [62],
can be considered an effect size of medium magni-
tude. As our design included three experimental con-
ditions (TIBP, TIBP + PA, WL), a between-groups
one-way ANOVA was assumed for the statistical ana-
lyses. Therefore, calculations of the necessary sample
size cannot be based on Hedges’ g index for effect
size, but rather on the f index [62]. Following Cohen
[62], f = 0.25 represents an effect size of medium
magnitude (and equivalent to g = 0.5). Thus, consid-
ering an alpha of .05 and a statistical power of .80,
the total sample size required to warrant these condi-
tions contains 159 participants (53 participants per
group). To control the maximum possible loss of sub-
jects during treatment, based on the literature about
Internet-based treatments, a 30% dropout rate is
expected [53, 63]. Thus, the required sample size
should have 207 participants in all (69 participants
per group). These calculations were accomplished
with the software program G*Power 3.1 [64].
Fig. 1 Flowchart of participants
Díaz-García et al. BMC Psychiatry  (2017) 17:145 Page 4 of 14
Study population, recruitment and eligibility criteria
The clinical trial will be conducted in a community sam-
ple of patients diagnosed with the aforementioned disor-
ders. Participants will be adult volunteers who contact us
because they are interested in the study (personal visits or
phone calls to the emotional disorders university clinic,
emails, or leaving their data on a website specially pre-
pared for this purpose). Potential participants will be
attended to by a psychologist who will describe the study
characteristics to them. All the psychologists working on
this study will have at least a master’s degree in Clinical
Psychology, with experience in the diagnosis, psycho-
logical assessment, and application of EBTs for ED.
The psychologist will clarify any doubts, ensure that the
participant has read the information about the study, and
make sure that s/he has understood the three experimen-
tal conditions. People interested in participating will sign
an online informed consent and be assessed taking into
account all the inclusion criteria. Inclusion and exclusion
criteria are shown in Table 1. If the patient fulfills all the
study criteria, the researcher will contact an independent
researcher to implement randomization. This researcher
will be unaware of the characteristics of the study.
Randomization will be performed using weighted random
allocation [65] in order to take into account the clinical
features (different diagnoses) and, thus, obtain a homoge-
neous distribution in the three experimental conditions.
Participants agree to participate before finding out to
which treatment they will be allocated. All participants
will be free to withdraw from the treatment at any time.
Ethics
The study follows the guidelines of the Declaration
Helsinki and existing guidelines in Spain and the Euro-
pean Union for the protection of patients in clinical tri-
als. As noted, all participants will be volunteers, and
they will sign the online informed consent to form part
of the study once it has been explained to them.
Participants will have the possibility of withdrawing from
the study at any time. The recruitment of participants
will be carried out by qualified personnel from a clinical
point of view. Participants allocated to the WL condition
will be offered the opportunity to receive the TIBP or
the TIBP + PA intervention after the waiting time has
ended. Based on the literature, no special difficulties are
expected. However, any undesired event would not only
mean the participant’s departure from the trial, but s/he
would also be offered the possibility of receiving psycho-
logical care at the Emotional Disorder Clinic in Universi-
tat Jaume I, or of being referred if his/her medical
condition required it.
A fundamental aspect in a project of this nature is
data protection. To protect information, strategies using
personal passwords and data via AES encryption (AES-
256; Advanced Encryption Standard) will be used. Per-
sonal data will be replaced by codes and data, which
must be collected by clinicians (e.g. age, sex, address,
and phone), stored separately from other data, and only
made available to researchers responsible for the study,
always protecting the right to privacy.
The study has been approved by the Ethics Committee
of Universitat Jaume I (Castellón, Spain). The trial was
registered at clinicalstrial.gov as NCT02578758.
Interventions
We have developed a manualized protocol, based on the
transdiagnostic perspective for the treatment of ED: MDD,
DD, OCD, PD, AG, GAD, SAD, ADNOS and MDNOS.
The treatment protocol is structured in a patient handbook
and a therapist handbook (Botella C, García-Palacios A,
Quero S, Baños R. A Transdiagnostic Treatment for
Emotion Disorders: Manualized Treatment Protocol,
unpublished). The modules in each intervention protocol
are described briefly in the following section.
We have adapted this protocol from classic perspectives
derived from the UP [9, 17] and some strategies from
Marsha Linehan’s protocol [66]. The protocol includes the
following core components mainly addressed to down-
regulate NA: present-focused emotional awareness and ac-
ceptance, cognitive flexibility, behavioral and emotional
avoidance patterns, and interoceptive and situational ex-
posure. The protocol also includes traditional therapeutic
components of evidence-based treatment for ED (Psy-
choeducation, Motivation for change, and Relapse preven-
tion). In addition, in order to promote psychological
strengths and enhance well-being [67], we have included a
PA-regulation component based on behavioral activation
strategies [68], strategies to promote pleasant and signifi-
cant activities linked to values and life goals, and strategies
to enhance personal strengths, positive feelings, positive
cognitions, and positive behavior [67, 69]. This component
also includes the Well-being Therapy (WBT) [70, 71]
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Minimal age of 18 years Suffering from Schizophrenia, bipolar
disorder, or alcohol and/or substance
dependence disorder
Meeting the DSM-IV diagnostic
criteria for ED
High risk of suicide
Ability to understand and read
Spanish
Medical disease/condition that
prevents the participant from carrying
out the psychological treatment
Access to Internet at home and
having an email address
Receiving another psychological
treatment during the study
Providing online informed
consent
An increase and/or change in the
pharmacological treatment (in the
case of receiving) during the study
period
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strategy of identifying examples of well-being and negative
cognitions (“interrupting thoughts”) that interfere with
these moments of well-being, in order to modify these
interfering cognitions. Some notions of Fredickson’s
Broaden-and-Build Theory are also included to explain the
mechanisms behind positive emotions [31].
Transdiagnostic Internet-based protocol (TIBP)
This intervention protocol consists of twelve more trad-
itional modules mainly designed to down-regulate NA.
Each module has specific objectives:
M1. Emotional disorders and emotion regulation. The
purpose of this module is to provide information about
the central role of emotion regulation in emotional
disorders. Brief descriptions of the program modules, as
well as videos with examples of people suffering from
different ED, are also presented.
M2. Motivation for change. The objective of this
module is to enhance motivation for change by
recognizing that attitudes towards change can be
ambivalent and that motivation fluctuates. The main
objective is to analyze the advantages and disadvantages
of changing, emphasize the importance of being
motivated, and highlight the importance of establishing
significant life goals.
M3. Understanding the role of emotions. This module
provides information about the adaptive roles and
functions of emotions. It also shows the three-
component model of emotions.
M4. The acceptance of emotional experiences. This
module focuses on the awareness and role of
acceptance of emotional experiences, as well as their
importance in the treatment.
M5. Practicing acceptance. The objective of this module
is to continue to learn about the acceptance of
emotional experiences and increase awareness of
physical sensations, thoughts, emotions, and daily
activities.
M6. Learning to be flexible. This module teaches
participants to be more cognitively flexible in order to
see life situations from different perspectives, showing
the importance of maladaptive ways of thinking and
learning how to identify them in the maintenance of
emotional disorders.
M7. Practicing cognitive flexibility. This module aims to
teach the patients how to modify maladaptive ways of
thinking. It also provides information about intrusive
thoughts and how to deal with them.
M8. Emotional avoidance. The aim is to teach the
patients emotion avoidance strategies that contribute to
the maintenance of emotional disorders.
M9. Emotion Driven Behaviors (EDBs). The aim is for
patients to learn the concept of EDBs and replace their
own maladaptive EDBs with other more adaptive
behaviors.
M10. Accepting and facing physical sensations. The
objectives are to teach the patients the role of physical
sensations in their emotional response and train them
in interoceptive exposure, in order to increase tolerance
and promote habituation to physical sensations.
M11. Facing emotions in the contexts where they occur.
This module aims to increase tolerance to emotions
and reduce avoidance behavior. The purpose is to
construct exposure hierarchies to help patients to begin
to face the avoided situations that contribute to the
maintenance of the problem.
Transdiagnostic Internet-based protocol + positive affect
component (TIBP + PA)
This intervention protocol is made up of 16 therapeutic
modules. The first 12 modules have been described above
in the first condition - (TIBP) - and the other 4 are aimed
to up-regulate PA by understanding and capturing positive
emotions, and training adaptive positive emotion regulation
strategies. These four modules are described as follows:
M12. Learning to move on. This module focuses on the
role of behavioral activation. The aim is to teach the
importance of ‘moving on’ in acquiring a proper level
of activity and involvement in life. It motivates the
patient to get involved in meaningful activities and
become engaged in his/her life.
M13. Learning to enjoy. This module helps the patient
to see the importance of positive emotions and teaches
procedures that generate positive experiences,
promoting involvement in pleasant and significant
activities and contact with others. This module involves
enjoying positive experiences and “savoring” positive
aspects of life in order to enhance wellbeing.
M14. Learning to live. This module takes a further step
in enhancing PA, understanding the importance of
identifying the individual’s own psychological strengths,
and selecting and carrying out meaningful activities
linked to values and goals in life. This module provides
strategies to achieve psychological well-being and resili-
ence. The aim is to improve the individual’ abilities and
live a life full of purpose and meaning.
M15. Living and learning. This module focuses on
developing an action plan to boost the individual’s
psychological strengths. It focuses on the importance of
developing and enhancing one’s own strengths and
starting to work for life and the future.
M16. Relapse prevention (this module is the same for
both conditions: (TIBP) and (TIBP + PA). It aims to
strengthen the strategies learned throughout the
program, schedule future practice, and teach how to
identify and cope with future high- risk situations.
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Adaptation to the web
This protocol has been adapted to a multimedia web
platform (video, images, etc.) and can be applied over
the Internet (https://www.psicologiaytecnologia.com/). It
is developed for optimal use on a PC or a tablet, and it
allows individuals to do the modules from their home
and at their own pace. The ease of use of the program
has been strengthened because it presents a streamlined
navigation, which allows users with less experience in
handling new technologies to know where they are and
how to keep moving forward at any time. The web adap-
tation of the protocol is the same in both conditions
(TIBP and TIBP + PA), with the only difference being
the inclusion or not of the modules that contain the PA-
regulation component.
Duration of the program can vary among users, and
participants in both treatment conditions have access to
the protocol for a maximum period of 18 weeks. The
program recommends working on one module for at
least one entire week, and it sends messages encouraging
the patient to continue to work to benefit from it. In
both conditions, the modules include exercises and tasks
to practice each technique and skill. Moreover, the plat-
form is ready to welcome all participants with informa-
tion about the treatment and its objectives, as well as
general information and recommendations about how to
benefit from it.
Regarding the assessment of patients within the pro-
gram, after the “Welcome”, initial online questionnaires
are presented as the pre-treatment assessment. In
addition, post-module brief questionnaires to evaluate
anxiety, depression, and positive/negative affect (OASIS,
ODSIS, PANAS) are also filled out throughout the pro-
gram. A noteworthy aspect of the program is that it al-
lows the therapist to have access to all this information
and receive an alert if the patient’s condition worsens.
The program includes suicide risk alarms that consist of
an email to the clinical team with information about a
high risk of suicide. These alarms are generated when
the system detects that the participant rated high on the
suicidal ideation items. It allows the clinician to contact
the patient and evaluate the actions that should be taken
to protect him/her. Finally, after the treatment, the par-
ticipants complete the online assessment in the post-
and follow-up periods.
All the modules are sequential, which allows the par-
ticipant to move through the program step by step. The
web platform was designed to optimize the understand-
ing of the modules’ content. It has different multimedia
elements (vignettes, videos, audios,...) that help the user
to assimilate the different psychological techniques in
the easiest way. The modules always follow the same
structure: they start with questions related to the previ-
ous module, continue with the specific contents of the
module, then propose the exercises, and finally present a
series of simple self-assessment questions designed to
verify whether the content presented has been under-
stood correctly. In addition, at the end of each module,
homework tasks are indicated to work on what was pre-
sented in the module. Performing these tasks helps to
consolidate everything learned in the program. Partici-
pants have the opportunity to obtain printable docu-
ments (PDF) with summaries of each module.
The web platform has four complementary tools that
appear on the main menu of the protocol: 1) “Home”,
which is the starting point from which the participant
can access the other sections of the protocol; 2) “Calen-
dar”, which is a tool that allows the participant to know
about pending or achieved tasks as well as his/her
current point in the program; 3) “Review”, which allows
the participant to review the treatment modules already
completed; and 4) “How am I?”, which allows partici-
pants to monitor their progress through a set of graphs.
It is a tool that provides feedback to participants about
their evolution during the program with regard to their
emotional distress (anxiety and sadness) and their posi-
tive and negative affectivity.
Support
In each of the two treatment conditions, we will provide
human support and ICT support to all participants.
Human support will be provided by weekly phone calls
(maximum of 5 min) during the treatment period in
order to resolve any difficulties or doubts about the use
of the online protocol, or to remind them of the import-
ance of doing the homework tasks and reviewing the
treatment contents. During these weekly phone calls, we
will also encourage participants to continue to use the
protocol, and reinforce them for engaging in the treat-
ment. At the end of the treatment period, participants
will be reminded that they will be contacted again for
follow-up assessments.
ICT support will consist of two weekly mobile
phone text messages reminding participants of the
importance of reviewing the modules and encouraging
them to do the homework tasks. Some examples of
these text messages are: “Hi there! Don’t hesitate to
review the modules you’ve already completed if neces-
sary. Remember, practice makes perfect!”or “Hi there!
Don’t give up on your module tasks! Dedicate some
time and effort to them. Remember, it’s ideal to
complete one module each week”. These messages
will be randomized, so that participants do not always
receive the same content. A professional platform will
be used to send these messages (www.trendoo.es).
The online treatment also contains several multiple-
choice questions about the contents seen in each
module. The program immediately provides the
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participant with the correct feedback and a simple
explanation. This aspect is repeated throughout all
the treatment modules. In addition, the ICT support
includes automatic e-mails with reminders to access
the program when participants have not entered in
the past 15 days.
Measures
Diagnostic interview
Mini International Neuropsychiatric Interview Version
5.0.0 (MINI) [72]. It is a short, structured, diagnostic
psychiatric interview for DSM-IV and ICD-10 diagnoses.
The MINI can be used by clinicians after a brief training
session. Nonclinical interviewers should receive more
intensive training. This interview has excellent inter-
rater reliability (k = .88–1.00) and adequate concurrent
validity with the Composite International Diagnostic
Interview [73]. The MINI has been translated and vali-
dated in Spanish [74].
Primary outcomes measures
Beck Depression Inventory (BDI-II) [75] It is one of
the most widely-used questionnaires in the evaluation of
depression severity. The BDI consists of 21 items, scored
on a scale from 0 to 3, covering all the different symp-
toms of major depression disorder. The total score on
this questionnaire can yield a maximum of 63 points.
The instrument has shown good internal consistency
(α = 0.76 to 0.95). The Spanish version of this instru-
ment has also shown high internal consistency
(α = 0.87) for both general and clinical populations
(α = .89) [76].
Beck Anxiety Inventory (BAI) [77] The BAI is a 21-
item symptom checklist designed to assess anxiety
symptoms. Each item is scored on a 0 to 3 point severity
scale, and the total scores range between 0 and 63. The
internal consistency of the BAI has been found to range
from .85 to .94. The Spanish version of the BAI has
shown high internal consistency (α = .93) [78].
Positive and Negative Affect Scale (PANAS) [79] The
PANAS consists of 20 items with a range from 1
(very slightly or not at all) to 5 (extremely). Respon-
dents have to indicate the extent to which they expe-
rienced the feeling or emotion during the past few
weeks. This scale evaluates two independent dimen-
sions: PA and NA. The maximum score for each sub-
scale is 50. The scale showed excellent internal
consistency (α between .84 and .90) and convergent
and discriminant validity. The Spanish version has
demonstrated high internal consistency (α = 0.89 and
0.91 for PA and NA in women, respectively, and
α = 0.87 and 0.89 for PA and NA in men, respect-
ively) in college students [80].
Secondary outcomes measures
Diagnosis-specific measures
Depending on each participant’s main diagnosis, differ-
ent instruments will be implemented.
– OCD: Obsessive-Compulsive Inventory-Revised
(OCI-R) [81]. The OCI-R is a short scale made up of
18 items rated from 1 to 4 to assess obsessive-
compulsive symptoms. The OCI-R yields six sub-
scales: washing, checking, ordering, obsessing,
hoarding, and neutralizing. The OCI-R has good
internal consistency (α = .81 to .93), good to excel-
lent test-retest reliability (α = .57 to .91), good con-
vergent validity, and a solid factor structure. The
Spanish version of the OCI-R has been found to be
good (α = .86) [82].
– PD/AG: Self-Reported Panic Disorder Severity Scale
(PDSS-SR) [83]. The PDSS-SR is a 7-item self-report
measure of panic disorder severity. This scale assesses
panic attack frequency, distress during panic attacks,
severity of anticipatory anxiety, fear and avoidance of
agoraphobic situations, fear and avoidance of physical
sensations, and work and social impairment. The scale
has shown excellent reliability (α = .917), test-retest
reliability (ICC = .81), and sensitivity to change. The
psychometric analysis of the Spanish version showed
excellent internal consistency (α = .85), good test-
retest reliability, and adequate convergent validity [82].
– GAD: Penn StateWorry Questionnaire (PSWQ) [84].
It is a questionnaire that evaluates symptoms related
to GAD. The PSWQ is a 16-item self-report question-
naire that assesses the tendency to worry, as well as
the intensity of the worry characteristic of GAD as an
uncontrollable, generalized, and excessive experience.
The PSWQ has demonstrated good internal
consistency ranging from .91 to .95, and good validity
and test-retest reliability. The Spanish version of the
scale showed an internal consistency of .90 and a test-
retest reliability of .82, as well as adequate convergent
and discriminant validity [85].
– SAD: Social Interaction Anxiety Scale (SIAS) [86].
This scale is a 20-item self-report measure rated on a
5-point scale ranging from 0 (not at all characteristic
or true of me) to 4 (extremely characteristic of me). It
assesses cognitive, affective, and behavioral reactions
in interactive social situations (symptoms related to
social phobia). The SIAS has high internal consistency
(α = .88 to .94) and good test-retest and discriminant
reliability, as well as adequate construct validity. The
Spanish validation of the scale showed adequate in-
ternal consistency [87].
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Personality measures
NEO-five factor Inventory The NEO FFI is the short
version of the NEO-PI-R [88], designed to assess the five
personality dimensions through 60 items. In this study,
only the subscales of neuroticism and extraversion are
used. Each scale contained 12 items with a five-point
Likert response format. Two-week retest reliability is
uniformly high, ranging from 0.86 to 0.90 for the five
scales [89], and internal consistency ranges from 0.68 to
0.86 [89].The Spanish version of the NEO FFI has been
found to be good [90].
Quality of life
EuroQol 5D (EQ-5D-Spanish version) [91] is a generic
instrument for measuring health-related quality of life. It
can be used in relatively healthy individuals (general
population) as well as in groups of patients with differ-
ent pathologies. Each individual rates his/her own health
on each of the two parts of the questionnaire. In the first
part, the individual must check the level corresponding
to his/her state of health in each of the five domains:
mobility, self-care, daily activities, pain/discomfort and
anxiety/depression. Each dimension is divided into three
levels of severity (without problems, some problems or
moderate problems, and severe problems), yielding a
population-based preference score or societal index (SI).
There are 243 possible combinations - health states -,
and the SI is calculated on the basis of these health
states. The index value ranges from 1 (best health state)
to 0 (death), although there are negative values for the
index corresponding to those health states that are rated
as worse than death. In the second part of the question-
naire, the individual values his/her own health on a more
general visual analogical scale (VAS), a 10 cm vertical
line on which the best and worst imaginable health
states score 100 and 0, respectively.
Suicidal ideation
A suicide item has been included within the ODSIS [92]
with the aim of obtaining a suicide risk indicator
throughout the treatment. The total score depends on
this single item, and the maximum score is 4, with a
range from 0 (“absence of thoughts of suicide”) to 4
("thoughts of suicide all the time").
Post-module measures
Scores on anxious and depressive symptomatology
will also be obtained after each module has been
completed.
Overall Anxiety Severity and Impairment Scale
(OASIS) [93] The OASIS consists of a 5-item question-
naire with a scale from 0 to 4, which measures the fre-
quency and severity of anxiety, as well as the level of
avoidance, work/academic/home interference, and social
and everyday life impairment related to anxiety symptoms.
The instructions tell the respondent to consider a wide
range of anxiety symptoms (e.g., panic attacks, worries,
flashbacks) when answering the questions, and the time
frame is “during the past week”. A psychometric analysis
of the OASIS scale found good internal consistency
(α = .80), test-retest reliability (k = .82) and convergent
validity for this instrument. The Spanish version of the
OASIS confirmed the factorial structure and reliability
and validity data obtained by the original authors (internal
consistency in both populations, general and clinical
(α = .0.86 and test-retest reliability (k = .84) [94].
Overall Depression Severity and Impairment Scale
(ODSIS) [92] The ODSIS is a self-report measure with
five items. Individuals select among five different re-
sponse options ranging from 0 to 4 for each item. This
scale evaluates experiences related to depression. The
ODSIS measures the frequency and severity of depres-
sion, as well as the level of avoidance, work/academic/
home interference, and social and everyday life impair-
ment related to depression symptoms. The ODSIS can
also be used to assess severity and impairment associ-
ated with low mood. In the Spanish version of the
ODSIS, the internal consistency has been shown to be
excellent, with a Cronbach’s alpha between .91 and .94
and good convergent and discriminant validity [95].
Expectation of treatment scale and opinion of treatment
scale.
The Expectation of Treatment Scale and Opinion of
Treatment Scale are questionnaires adapted from Borko-
vec and Nau [96]. Each scale contains five items, rated
from 0 (“strongly disagree”) to 10 (“strongly agree”),
which cover how logical the treatment seemed, to what
extent it could satisfy the patient, whether it could be
used to treat other psychological problems, and its use-
fulness for the patient’s specific problem. The expect-
ation scale is applied once the intervention has been
explained, at the end of the “Welcome module”. This
scale measures the patient’s subjective expectations
about the treatment. In addition, the opinion scale is ad-
ministered when the patient has completed the treat-
ment, and its aim is to assess satisfaction with the
intervention. Our group has used this questionnaire in
several research studies [48, 97].
The study measures and assessment times are summa-
rized in Table 2.
Data analyses
Intention-to -treat analyses and per protocol analyses
will be performed, and CONSORT recommendations
will be followed [98]. First, the three groups will be
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compared to verify that there are no significant differ-
ences among them at baseline on the outcome measures
in order to confirm that they are comparable after
randomization. One-way ANOVAs for continuous vari-
ables and Chi-squared tests of independence for categor-
ical ones will be used. For the continuous outcome
measures on the posttest, the homoscedasticity assump-
tion will be assessed with the Levene test. Where this as-
sumption is met, the usual F-test will be applied to
compare the posttest means for the three experimental
conditions. If the homoscedasticity assumption is not
met, the Brown-Forsythe F-test will be applied. Statisti-
cally significant F-tests will be followed by post hoc
comparisons. In particular, the Tukey procedure will be
applied where the homoscedasticity assumption is met,
and the Games-Howell procedure if this assumption is
not met.
The intention-to-treat principle will be used when
analyzing primary and secondary post-treatment data
and data collected at the 3- and 12-month follow-
ups, using mixed-effect models with full information
maximum likelihood estimation. This method has
been recommended due to its flexibility on repeated-
measures ANOVAs in handling missing data more
appropriately [99]. To complement the results of the
ANOVAs and post hoc comparisons, effect sizes will
be calculated by using the standardized mean differ-
ence proposed by Cohen [62]. These effect sizes will
be calculated to assess both within- and between-
group changes, all of them based on a pooled stand-
ard deviation.
Although per protocol analyses (completers only ana-
lysis) suffer from selection bias, they will also be con-
ducted to help to draw conclusions about the maximum
treatment efficacy in patients who comply fully with the
treatment [100].
When the trial ends, the analytic methodology for the
RCT will be reviewed before analyzing the data in order
to select the most appropriate analytic procedures.
Discussion
This study describes a new Internet-based transdiagnos-
tic treatment protocol for patients diagnosed with ED.
One of the core aims of this study is to provide data
from an RCT to evaluate the efficacy of this protocol in
a community sample, compared to a waiting list group.
This protocol includes the transdiagnostic cognitive-
behavioral principles [17] designed for a wide range of
anxiety and depressive disorders to down-regulate NA,
and it also incorporates a specific treatment component
to address PA. These two ways of delivering the protocol
will be tested in order to explore the effect of adding a
specific therapeutic component to up-regulate PA.
Moreover, the aim of the present study is to make
progress in resolving some of the challenges in the field
of mental health [101], specifically in understanding the
necessary treatment components to modify clinical
symptoms (depression and anxiety) and strengthen
Table 2 Study measures and assessment times
Measure Aim Time of assessment
MINI Neuropsychiatric Interview Diagnosis BL, Post-T and FU
PANAS Positive and negative affect Post-T and Post-module
BDI-II Severity of depression BL, Post-T and FU
BAI Severity of anxiety BL, Post-T and FU
OCI-R Severity of OCD symptoms BL, Post-T and FU
PDSS-SR Severity of PD and
agoraphobia symptoms
BL, Post-T and FU
PSWQ Severity of GAD symptoms BL, Post-T and FU
SIAS Severity of SAD symptoms BL, Post-T and FU
NEO FFI Neuroticism and Extraversion BL, Post-T and FU
EQ-5D Health-related quality of life BL, Post-T and FU
OASIS Severity of anxiety Post-module
ODSIS Severity of depression Post-module
Suicide item Suicidal ideation BL, Post-module, Post-T and FU
Expectation of Treatment Scale Expectation of treatment BL
Opinion of Treatment Scale Opinion of treatment Post-T
BL, Baseline; Post-T, post-treatment; FU, follow-ups, 3 and 12-month follow-ups; PANAS, Positive and Negative Affect Scale; BDI-II, Beck Depression Inventory-II; BAI, Beck
Anxiety Inventory; OCI-R, Obsessive-Compulsive Inventory-Revised; PDSS-SR, Self-Reported Panic Disorder Severity Scale; PSWQ, Penn State Worry Questionnaire; SIAS, Social
Interaction Anxiety Scale; NEO FFI, NEO-Five Factor Inventory; EQ-5D, EuroQoL-5D questionnaire; OASIS, Overall Anxiety Severity and Impairment Scale; ODSIS, Overall
Depression Severity and Impairment Scale
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people’s resilience, making them less vulnerable [101,
102].The potential impact on basic personality dimen-
sions (N/NA/BI) and (E/PA/BA) will also be studied. As
Barlow suggests [102], personality dimensions may be
malleable over time, and so it can be relevant to study
the “malleability” of neuroticism. Likewise, the study will
also examine whether it is possible to develop strategies
to modify PA (extraversion). There is growing support in
the literature for the claim that positive emotions pro-
mote flexible and creative thinking and play a funda-
mental role in the construction of psychological
strengths and intellectual and social resources that can
be useful in difficult situations in the future [103–106].
Some studies have proposed ways to address both the
assessment and treatment of PA regulation from a trans-
diagnostic perspective [28, 107], but further research is
needed on this topic. This study aims to explore the ef-
fect of treatment components on increasing wellbeing
and PA. If this is confirmed, it would certainly represent
an important shift in the research, understanding, as-
sessment, and treatment of ED. To the best of our
knowledge, this is the first study of an RCT testing an
online transdiagnostic treatment protocol for ED with a
specific therapeutic component to directly up-regulate
PA.
The data obtained with this study can be compared to
results obtained in studies with face-to-face transdiag-
nostic protocols using benchmarking strategies [33]. In
addition, the data will also be compared to transdiagnos-
tic protocols applied over the Internet, but without com-
ponents for up-regulating PA [15, 108–112].
The objective of establishing action strategies to im-
prove access to EBTs should also be taken into consider-
ation, as well as the goal of providing psychological
support to all those in need [5]. Undoubtedly, we are
witnessing the beginning of a new era in the field of psy-
chological treatments. They have already gone beyond
traditional EBTs, and now it is possible to manage these
online protocols with good results [53]. The use of tech-
nology and the Internet can help to disseminate and in-
crease the access to these interventions.
Finally, we will test the effectiveness of the application
of this Internet-based program with minimal support
from the clinician, and the acceptability of this online
program in patients from a community sample.
We are aware that this study has limitations. One of
the most important is the different number of modules
in the two protocols. We tried to control this by giving
all the participants equal time and allowing them to use
the program as much as they like throughout the whole
process. However, in order to test the potential add-
itional impact of the positive psychology component, it
seemed necessary to compare it to the traditional trans-
diagnostic protocol. If the new component is found to
have any effect, future research should be carried out to
show that this effect is not simply due to the larger
number of modules in the protocol.
There are further limitations. For example, dropout
rates are expected to be high (around 30%) [53, 63]. To
minimize this problem, human and ICT support will be
provided. In addition, another limitation may be recruit-
ment difficulties, to the extent that people still do not
have access to the Internet at home, or they have nega-
tive attitudes towards Internet interventions.
In summary, this study aims to contribute to the lit-
erature on the efficacy of transdiagnostic approaches to
ED in general, and it more specifically seeks to explore
the possible impact of specific component designed to
up-regulate positive affect. Despite its limitations, if
positive results are achieved, they will have a clear
impact on the design and application of future transdiag-
nostic treatment protocols for ED, as a way to more
effectively address the temperament vulnerabilities, that
is, the core aspects of these disorders [102].
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